SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency human immunoglobulin G (hIgG) therapies for immune and autoimmune disorders. The company uses its proprietary Tc-Bovine™ (transchromosomic cattle) technology platform to produce fully human antibodies without requiring human donors or convalescent plasma. Its lead product candidate, SAB-142, is being developed as a disease-modifying immunotherapy for Type 1 Diabetes (T1D), with the goal of delaying disease progression and preserving beta-cell function. The company has conducted multiple clinical trials involving more than 700 participants across several therapeutic areas. SAB Biotherapeutics operates primarily in the United States and is advancing clinical development programs targeting significant unmet medical needs in autoimmune diseases.